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Abstract
Embryonic stem (ES) cells have the potential to differentiate into all cell types and are considered as a valuable source of
cells for transplantation therapies. A critical issue, however, is the risk of teratoma formation after transplantation. The effect
of the immune response on the tumorigenicity of transplanted cells is poorly understood. We have systematically compared
the tumorigenicity of mouse ES cells and in vitro differentiated neuronal cells in various recipients. Subcutaneous injection
of 1610
6 ES or differentiated cells into syngeneic or allogeneic immunodeficient mice resulted in teratomas in about 95% of
the recipients. Both cell types did not give rise to tumors in immunocompetent allogeneic mice or xenogeneic rats.
However, in 61% of cyclosporine A-treated rats teratomas developed after injection of differentiated cells. Undifferentiated
ES cells did not give rise to tumors in these rats. ES cells turned out to be highly susceptible to killing by rat natural killer
(NK) cells due to the expression of ligands of the activating NK receptor NKG2D on ES cells. These ligands were down-
regulated on differentiated cells. The activity of NK cells which is not suppressed by cyclosporine A might contribute to the
prevention of teratomas after injection of ES cells but not after inoculation of differentiated cells. These findings clearly
point to the importance of the immune response in this process. Interestingly, the differentiated cells must contain a
tumorigenic cell population that is not present among ES cells and which might be resistant to NK cell-mediated killing.
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Introduction
Embryonic stem (ES) cells are a potential source of cells and
tissues for transplantation in regenerative medicine. However, one
of the critical issues is the risk of teratoma formation after
transplantation of ES cells. It has been reported, e. g., that
undifferentiated mouse ES cells can develop into functional
dopaminergic neurons after intrastriatal transplantation in a rat
model of Parkinson’s disease but teratomas occurred in about 20%
of the recipients which had been treated with cyclosporine A (CsA)
for immunosuppression [1]. Transplantation of dopaminergic
neurons differentiated in vitro from ES cells improved amphet-
amine-induced rotational behavior in the unilaterally 6-hydroxy-
dopamine (6-OHDA)-lesioned rat model for Parkinson’s disease
[2]. These rats which were continuously treated with CsA did not
develop teratomas [2]. Functional improvements without the
development of teratomas have been observed after transplanta-
tion of neuronal cells differentiated from ES cells on PA6 feeder
cells into the striata of 6-OHDA-lesioned rats which had not
received any immunosuppressive treatment [3]. Despite the
behavioral changes of the transplanted animals, the grafted cells
remained in compact deposits surrounded by glia cells without
functional integration into the host tissue [3], which is postulated
for an optimal long-term survival of grafts. When these in vitro
differentiated neuronal cells were transplanted into CsA-treated
recipients, tyrosine hydroxylase (TH)-positive neurites were
present in the grafts suggesting a better integration of transplanted
cells, however, now teratomas occurred in 2 of 15 animals [4]. In
all these experiments a xenotransplantation was performed
because rat ES cells are not readily available whereas the rat
model allows for a reliable functional evaluation of grafts. The
results might suggest that immunosuppression is required for
functional integration of grafted cells but is associated with the risk
of teratoma formation. Systematic comparative studies which
address these questions are lacking. In one study a higher
prevalence of teratomas was observed after intracerebral trans-
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that the tumorigenesis of ES cells partially depends on the host [5].
Teratomas have been found also after injection of ES or in vitro
differentiated cells into various other tissues including, e.g., liver
[6] and myocardium [7–9].
It has been proposed that teratoma formation can be prevented
by in vitro pre-differentiation of ES cells [2] although conflicting
results have been reported as well [4,5]. In accordance with this
hypothesis transplantation of ES cells into immunosuppressed
allogeneic mice frequently leads to teratomas but in vitro pre-
differentiation can reduce the tumorigenicity of the grafts [10].
Sorting of cells expressing the neural precursor marker Sox1
before transplantation has been shown to further reduce the risk of
teratoma formation [10,11]. Furthermore, it has been reported
that neuronal precursors can be enriched by inducing apoptosis in
pluripotent stem cells using ceramide analogues so that teratoma
formation is avoided [12]. These results are compatible with the
common hypothesis that only undifferentiated stem cells can give
rise to teratomas and that teratoma formation after injection of
differentiated cells is caused by contamination of the grafts with
undifferentiated cells.
In general, the effect of the immune response on the
tumorigenicity of transplanted undifferentiated ES cells and in
vitro differentiated cells is important but still poorly understood.
Therefore, we systematically compared the tumorigenicity of
mouse ES cells and in vitro differentiated neuronal cells after
subcutaneous injection in immunocompetent and immunosup-
pressed syngeneic, allogeneic, and xenogeneic hosts.
Results
Tumorigenicity of ES cells and differentiated cells in
syngeneic but not in allogeneic or xenogeneic hosts
We analyzed the tumorigenicity of ES cells (MPI-II) and ES
cell-derived neuronal cells which were differentiated in vitro for 14
days in syngeneic, allogeneic, and xenogeneic hosts. Since we
expected that ES cells would give rise to teratomas in syngeneic
129Sv mice, we determined the number of ES cells that were
necessary to achieve tumor growth after subcutaneous injection in
the majority of mice. Within 100 days tumors were observed in all
mice which received at least 1610
6 ES cells (Table 1). Therefore,
the subsequent experiments were performed with a dose of
1610
6 cells.
Syngeneic (129Sv), and allogeneic (C57BL/6 and C3H/HeN)
mice as well as xenogeneic (LOU/c) rats were used as recipients.
129Sv and C57BL/6 mice share the major histocompatibility
complex (MHC) haplotype H2
b. These mice differ therefore only
in minor histocompatibility antigens, but not in the major
histocompatibility antigens, i.e., the classical MHC class I and
class II molecules. C3H/HeN mice carry the MHC haplotype H2
k
and differ in major and minor histocompatibility antigens from
129Sv mice. Injection of 1610
6 ES cells or differentiated cells into
syngeneic hosts resulted in about 95% of the animals in palpable
tumors at the site of injection within 100 days post injection
(Table 2). In a few cases tumors that were palpable at least in 3
consecutive observations did not continue to grow and disap-
peared before day 100. Tumors grew early and rapidly in some
animals, whereas small tumors remained stable for the whole
observation time in others (Fig. 1). We did not observe a
statistically significant difference in the growth of tumors after
injection of ES and differentiated cells, although a trend
(p=0.0673) towards a reduced growth of differentiated cells was
observable (Fig. 1). The growth of tumors was accelerated in male
compared to female hosts (p,0.0001) after injection of the male
ES cells (XY karyotype). We then determined the frequency of
tumor growth after injection of various cell numbers of
differentiated cells and observed a similar cell dose dependency
as before for ES cells (Table 1).
At the end of the experiments all animals underwent autopsy.
No signs of regional or distant metastases were found. Histopath-
ological evaluation identified all tumors as teratomas (Fig. 2A, B).
Derivatives of the three germ layers were regularly observed
during histopathological analysis of the tumors arising after
injection of ES as well as in vitro differentiated cells. In agreement
with the rapid growth of the tumors, the proliferation marker Ki67
was regularly detected by immunohistochemistry (Fig. 2F, Table 3).
The pluripotency marker OCT3/4 (POU5F1) was not found to be
expressed (Table 3). T and B lymphocytes as well as macrophages
were present in most teratomas (Fig 2C–E, Table 3) but obviously
not able to prevent tumor growth in syngeneic mice. In several
teratomas B cells appeared even to form lymph follicle-like
Table 1. Tumor formation after subcutaneous inoculation of
various numbers of ES cells or in vitro differentiated cells in
129Sv mice.
Cell number ES cells differentiated cells (d 14)
2610
6 100% (6/6) 100% (6/6)
1610
6 100% (6/6) 83% (5/6)
5610
5 33% (2/6) 17% (1/6)
1610
5 17% (1/6) 0% (0/6)
The indicated number of ES cells and cells differentiated in vitro for 14 days
were injected subcutaneously into the flank of 129Sv mice. The percentage and
number of animals is indicated in which tumors were found during autopsy at
the side of injection before day 100 after injection.
doi:10.1371/journal.pone.0002622.t001
Table 2. Tumor formation after subcutaneous inoculation of
ES or in vitro differentiated cells into various hosts.
host CsA ES cells
differentiated
cells (d 14)
syngeneic (129Sv, H2
b) 2 96% (25/26)
1 95% (21/22)
2
allogeneic (C57BL/6, H2
b) 2 0% (0/19) 0% (0/25)
allogeneic (C3H, H2
k) 2 0% (0/13) 0% (0/21)
xenogeneic (LOU/c, RT1
u) 2 0% (0/12) 0% (0/17)
allogeneic SCID/beige (C.B-17, H2
d) 2 93% (13/14)
3 94% (17/18)
4
syngeneic (129Sv, H2
b) + 94% (15/16)
5 83% (10/12)
allogeneic (C57BL/6, H2
b) + 0% (0/12) 8% (1/13)
allogeneic (C3H, H2
k) + 7% (1/15) 9% (1/11)
xenogeneic (LOU/c, RT1
u) + 0% (0/25) 61% (11/18)
6
ES cells and cells differentiated in vitro for 14 days were injected subcutaneously
into the flank of syngeneic or allogeneic mice or xenogeneic rats (1610
6 cells in
PBS/animal). Some recipients received an immunosuppressive treatment with
CsA (10 mg/kg/day). The percentage and number of animals in which tumors
were found during autopsy or in which tumors were palpable (at least during 3
consecutive observations) at the side of injection before day 100 after injection
is indicated.
1in 2 mice (8%) a tumor regression was observed before day 100.
2in 2 mice (9%) a tumor regression was observed before day 100.
3in 1 mouse (7%) a tumor regression was observed before day 100.
4in 2 mice (11%) a tumor regression was observed before day 100.
5in 8 female mice (47%) a tumor regression was observed before day 100.
6in 2 rats (11%) a tumor regression was observed before day 100.
doi:10.1371/journal.pone.0002622.t002
Immune Rejection of ES Cells
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and glial cells was not different when tumors arising from ES cells
and differentiated cells were compared (Table 4).
Both cell types, ES and differentiated cells, did not give rise to
tumors in xenogeneic LOU/c rats and in completely allogeneic
C3H/HeN mice (Table 2). Differences in minor histocompatibility
antigens were sufficient to prevent progressive tumor growth
because C57BL/6 recipients did also not develop tumors (Table 2).
Thus, the immune system appears to be able to prevent tumor
growth after injection of ES and differentiated cells into allogeneic
or xenogeneic hosts.
Low frequency of undifferentiated cells in the
differentiation cultures
In syngeneic recipients both cell types led to tumors in similarly
high frequency (,95%), indicating the presence of tumorigenic
cells also after differentiation culture. However, in accordance with
our previous data [3] less than 5% of the colonies in the
differentiation cultures at day 14 contained cells positive for
OCT3/4 and Ki67 (Fig. 3A–C) which might represent still
undifferentiated ES cells. Ki67-positive but OCT3/4-negative
cells were also found in these rare colonies (Fig. 3C). Importantly,
the vast majority of the cells in the differentiation cultures were III
b-tubulin (Tuj1)-positive indicating a neuronal differentiation
(Fig. 3D). The few proliferating Ki67-positive cells were negative
for neuronal markers (Fig. 3D). In view of these characteristics of
the in vitro differentiated cells, it was surprising that teratomas were
equally frequent in syngeneic mice after injection of this
heterogeneous but mainly neuronal cell population and a
homogenous undifferentiated ES cell population.
Tumorigenicity of ES cells and differentiated cells in
allogeneic immunodeficient hosts
To verify that the suppression of tumor growth in allogeneic
hosts was indeed dependent on the immune system, the cells were
injected into allogeneic SCID/beige mice which lack T and B
lymphocytes as well as functional natural killer (NK) cells. In these
recipients teratomas grew in similar frequency as in syngeneic
hosts (Table 2). No significant difference of tumor growth was
observed after injection of ES and differentiated cells (Fig. 1B).
Interestingly, several teratomas of SCID/beige mice expressed
OCT3/4 (Fig. 2G) in contrast to the tumors grown in syngeneic
129Sv mice (Table 3), suggesting a removal of those cells in
immunocompetent mice. The teratomas grown after injection of
Figure 1. Tumor growth in syngeneic 129Sv and immunodeficient SCID/beige mice after injection of ES cells or in vitro differentiated
cells.(A)1610
6EScells(MPI-II)orinvitrodifferentiatedcells(day14ofdifferentiationculture)wereinjectedsubcutaneouslyatday0intosyngeneic129Sv
mice (for the numbers of animals see Table 2). The tumor size was recorded every second day until day 100 using linear calipers. The growth of tumors in
individual mice is shown. Tumor growth in female hosts is indicatedby red and in male hosts bybluelines. (B) 1610
6 EScells or in vitro differentiated cells
were injected subcutaneously at day 0 into immunodeficient SCID/beige mice which are deficient for T, B, and functional NK cells.
doi:10.1371/journal.pone.0002622.g001
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and glial markers (Fig. 4) and both cell types were found in a
similar frequency (Table 4).
PA6 feeder cells are not responsible for tumors observed
after injection of differentiated cells
Differentiated cells were obtained by culturing MPI-II ES cells
on a feeder layer of mitomycin-inactivated PA6 cells. We wanted
to exclude that PA6 cells (derived from a C57BL/6 mouse) [13]
could have contributed to the tumors. Therefore, we injected
1610
6 viable PA6 cells into groups of 6 to 8 C57BL/6, 129Sv,
C3H/HeN, SCID/beige mice, and LOU/c rats. We did not
observe any signs of tumor growth in these animals (data not
shown). Thus, PA6 cells are not tumorigenic and do not contribute
to the tumor growth after injection of differentiated cells.
Effect of immunosuppression on tumorigenicity of ES
cells and differentiated cells in various hosts
After experimental transplantation of ES cells immunosuppres-
sion is frequently used to avoid rejection of the transplanted cells.
Therefore, we determined the effect of immunosuppression on the
tumorigenicity of the cells. In 129Sv mice treated with CsA
(10 mg/kg/day) we observed teratomas in a similar frequency as
in untreated animals (Table 2). Interestingly, 8 of 10 female CsA-
treated 129Sv mice injected with ES cells were able to reject the
tumors within 100 days and in only one female a tumor was
Figure 2. Histopathological analysis identifies tumors from ES and in vitro differentiated cells as teratomas. Tumors grown in 129Sv
mice after injection of ES cells (A) or after injection of in vitro differentiated cells (B) were HE stained. The tumors are teratomas which show various
differentiations. Teratomas from 129Sv mice were stained by immunohistochemistry for macrophages (C), T lymphocytes (D), B lymphocytes (E), and
the proliferation marker Ki67 (F). Some teratomas grown in SCID/beige mice (G) and CsA-treated rats (H) expressed OCT3/4, a marker of pluripotent
cells.
doi:10.1371/journal.pone.0002622.g002
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mice formed tumors in 6 of 6 cases (Fig. 5A). Thus, immunosup-
pression appeared to be associated with regression of ES cell-
derived tumors in female 129Sv recipients. Differentiated cells
formed tumors in 4 of 6 male and 6 of 6 female CsA-treated 129Sv
mice. In CsA-treated mice tumor growth appeared to be
accelerated in male animals after injection of ES cells
(p,0.0180) and in female mice after injection of differentiated
cells (p,0.0001). Thus, the tumor growth might depend on a
complex interaction between the injected cell type and sex of the
host (p,0.0001). We did not observe a similar interaction of these
factors in the untreated 129Sv mice (p=0.8198). The progres-
sively growing teratomas expressed Ki67 but no OCT3/4
(Table 3). Interestingly, also the infiltration of the teratomas by
T and B lymphocytes was not altered compared to the mice which
did not receive CsA (Table 3).
In CsA-treated allogeneic C57BL/6 and C3H/HeN mice small
tumors (,10 mm
3) were detected in single cases (Table 2).
However, injection of ES cells and differentiated cells did not lead
to progressive tumor growth in CsA-treated allogeneic mice. Most
surprisingly, injection of differentiated cells into CsA-treated
LOU/c rats resulted in 11 of 18 cases in teratomas (Table 2).
Tumor growth was observed in 9 of 9 male rats (Fig. 5B). In two of
Table 3. Results of immunohistochemical stainings of teratomas grown in various hosts.
host CsA cells OCT3/4 Ki67 T cells B cells macrophages
129Sv 2 ES 2 ++ 2 to +++ + to +++ +
129Sv 2 diff. 2 ++ 2 to ++ 2 to +++ +
129Sv + ES 2 ++ 2 to ++ 2 to +++ +
129Sv + diff. 2 ++
1 ++ to +++ ++ to +++ +
SCID/beige 2 ES 2 to ++ ++ n. t.
2 n. t. +
SCID/beige 2 diff. 2 to ++ ++
1 n. t. n. t. +
LOU/c
3 + diff. 2 to ++ +
1 + to +++ ++ to +++ ++ to +++
1
Teratomas were obtained after injection of ES cells or differentiated (diff.) cells into syngeneic 129Sv mice, immunodeficient SCID/beige mice or LOU/c rats. Some
recipients received CsA (10 mg/kg/day). Histological sections were stained by immunohistochemistry for OCT3/4, Ki67, T cells (anti-mouse or anti-rat CD3), B cells (anti-
mouse CD45R/B220 or anti-rat CD45R), and macrophages (anti-mouse Mac3 or anti-rat CD68). The presence of the markers is indicated semi quantitatively in four
categories: 2 negative, + single positive cells, ++ groups of positive cells, +++ confluent groups of positive cells. Five representative teratomas per group of mice and 9
teratomas of LOU/c rats were analyzed.
1One not rapidly growing tumor in each of these groups was negative for the marker.
2not tested.
3Teratomas grown in LOU/c rats were stained for infiltrating rat T and B cells as well as rat macrophages.
doi:10.1371/journal.pone.0002622.t003
Table 4. Expression of neuronal and glial markers in
teratomas grown in 129Sv and SCID/beige mice after injection
of ES and differentiated cells.
host cells NeuN GFAP
129Sv ES + to +++ 2 to +++
1
129Sv diff. 2 to ++
2 2 to +++
1
SCID/beige ES 2 to +++
1 + to ++
SCID/beige diff. +to +++ ++ to +++
Teratomas were obtained after injection of ES cells or differentiated (diff.) cells
into syngeneic 129Sv mice and immunodeficient SCID/beige mice. Histological
sections were stained by immunohistochemistry for the neuronal marker NeuN
and the glial marker GFAP. The presence of the markers is indicated semi
quantitatively in four categories: 2 negative, + single positive cells, ++ groups
of positive cells, +++ confluent groups of positive cells. Five representative
teratomas per group were analyzed.
12 of 5 teratomas were negative for this marker.
23 of 5 teratomas were negative for this marker.
doi:10.1371/journal.pone.0002622.t004
Figure 3. Some of the ES cell-derived neuronal colonies still
contain at day 14 OCT3/4 and Ki67-positive cells. (A) After 14
days of differentiation culture few colonies (less than 5%), as
exemplified here, still contain OCT3/4-positive cell clusters as detected
by immunofluorescence staining using a specific mAb (magnification
406). (B) The same colony was stained by an anti-Ki67 mAb to detect
proliferating cells. (C) The merged staining indicates that Ki67-positive
proliferating cells exist which are not OCT3/4-positive stem cells. (D) In
parallel, cells of the neuronal differentiation culture were stained at day
14 by anti-Ki67 and anti-Tuj1 mAb. The merged staining (magnification
206) indicates that the vast majority of the cells are Tuj1-positive
neuronal cells. Few Ki67-positive proliferating cells are negative for the
neuronal cell marker.
doi:10.1371/journal.pone.0002622.g003
Immune Rejection of ES Cells
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detected in 2 of 9 female rats within 100 days after inoculation
(Fig. 5B). It is important to notice that none of the CsA-treated rats
(including 12 males and 13 females) developed tumors after injection
of ES cells (Table 2). Thus, the tumorigenicity of ES cells compared
to differentiated cells was clearly reduced in CsA-treated rats
(p,0.0001). After injection of differentiated cells the tumor growth
was clearly dependent on the CsA treatment (p,0.0001) and on the
sex of the host (p=0.0127). The teratomas grown in the rats
expressed Ki67 with exception of one non-progressive tumor. 5 of 9
teratomas expressed some OCT3/4 (Fig. 2H), as teratomas in
immunodeficient mice did. However, it is not clear whether these
OCT3/4-positive cells are ES cells from the grafts which survive
when transplanted as contaminants of the tumorigenic differentiated
cells or whether they represent another undefined cell population.
All teratomas showed infiltration with rat T and B lymphocytes as
well as rat macrophages (Table 3). Rat NK cells were rarely found in
these fully established tumors (data not shown).
These experiments clearly demonstrate that tumorigenic cells
are present among the in vitro differentiated cells which are not
undifferentiated ES cells. Furthermore, it appears that the
tumorigenicity of mouse ES cells in contrast to differentiated cells
is controlled by a part of the rat’s immune system which is not
suppressed by CsA.
Susceptibility of ES cells to natural cytotoxic cells and
expression of ligands for inhibitory and activating NK
receptors
CsA is known to suppress the adaptive immune system by
interfering with T cell signaling. We suspected that a natural
cytotoxic activity that is not suppressed by CsA was able to prevent
the growth of tumors derived from ES cells but not from
differentiated cells. Therefore, we analyzed the susceptibility of ES
cells and differentiated cells to killing by splenocytes derived from
naı ¨ve LOU/c rats. ES cells in contrast to differentiated cells were
killed readily in chromium release assays by splenocytes from
LOU/c rats (Fig. 6A). No differences in the cytotoxic activity
between splenocytes of male and female rats were found.
Lymphocytes derived from lymph nodes of the same animals did
not show a cytotoxic activity against these targets (data not shown).
Similar results were obtained when effector cells from other rat
strains were used (see below Fig. 7). These results were in
agreement with the assumption that NK cells, which are abundant
in the spleen but rare in lymph nodes, can kill ES cells. We further
isolated rat NK cells from spleens of naı ¨ve LOU/c rats by
magnetic cell sorting of NKR-P1A-positive NK cells and used
them directly without prior cytokine stimulation as effector cells in
cytotoxicity assays against ES target cells. The purified NK cells
were able to kill the ES cells and the typical NK target cell line
YAC-1 in contrast to RMA cells which are known to be resistant
to NK cells (Fig. 6B). The cytotoxic activity of the NK cells could
be inhibited by ethyleneglycol-bis(b-aminoethyl ester)-N,N,N9,N9-
tetraacetic acid (EGTA, data not shown), indicating that the
granule exocytosis pathway was used to kill the targets. The NK
cell-depleted splenocyte fraction was not able to kill any of these
target cell lines even at much higher effector target ratios (Fig. 6B).
Thus, the mouse ES cells were indeed susceptible to rat NK cells.
We wondered why mouse NK cells were not able to suppress the
teratoma growth in 129Sv mice after injection of ES cells.
Interestingly, freshly isolated NK cells of naı ¨ve 129Sv mice
completely failed to kill the ES cells. However, a short term culture
in the presence of interleukin (IL)-2 was sufficient to activate them
Figure 4. Immunohistochemical staining identifies neuronal and glial cells in teratomas derived from ES and in vitro differentiated
cells. The tumors were grown in SCID/beige mice after injection of ES cells (A, C) or after injection of in vitro differentiated cells (B, D). The teratomas
were stained by immunohistochemistry for the neuronal marker NeuN (A, B) and the glial marker GFAP (C, D) which is mainly found in astrocytes. In
the sections shown here, groups of cells positive for NeuN and confluent groups of cells positive for GFAP were found.
doi:10.1371/journal.pone.0002622.g004
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preexisting cytotoxic activity against ES cells (Fig. 6C).
The cytotoxic activity of NK cells is known to be controlled by a
set of inhibitory and activating NK receptors which are expressed
on NK cells and interact with certain ligands on target cells.
Ligands of inhibitory NK receptors are classical class I molecules,
such as H2K and H2D. Ligands of activating NK receptors, such
as NKG2D, include in the mouse the RAE-1 family as well as
MULT-1 and H60 molecules. We determined the expression of
classical MHC class I molecules (H2K
b and H2D
b) and NKG2D
ligands on ES and differentiated cells by flow cytometry (Fig. 6D).
MHC class I molecules were not detectable on ES cells but slightly
up-regulated during differentiation. NKG2D ligands showed
clearly the opposite expression pattern and were expressed only
in ES cells (Fig. 6D). The RAE-1 proteins were the NKG2D
ligands expressed on the ES cells (Fig. 6E). NKG2D ligands on ES
cells were most likely responsible for the susceptibility of these cells
to rat NK cells since the NK cell-mediated killing could be blocked
by a soluble NKG2D protein (Fig. 6F). Similarly, the killing by
activated mouse NK cells could be inhibited by the soluble
NKG2D protein and also by inhibitory antibodies against RAE-1
molecules (Fig. 6G).
Cellular cytotoxicity against ES cells in rats after
intracerebral grafting of differentiated cells
Rats are widely used as hosts to evaluate functional properties of
cells which are differentiated in vitro from mouse ES cells [1,2]. The
differentiated cells analyzed here were evaluated previously for
their therapeutic potential in a rat model of Parkinson’s disease
[3,4]. In this model 10
5 differentiated cells were transplanted into
the striata of unilaterally 6-OHDA-lesioned rats. We now analyzed
the cytotoxic activity of effector cells from transplanted rats 6
weeks after intrastriatal grafting. Rats from two inbred rat strains
(DA and LEW.1N) and one outbred strain (Wistar) were used as
recipients in these experiments. The animals did not receive any
immunosuppressive therapy after transplantation. No teratomas
were found in the brains of these animals (data not shown),
confirming our previous observations [3].
Freshly isolated splenocytes from 4 of 5 grafted and two
untreated control DA rats killed ES cells in chromium release
assays at least to certain extend (Fig. 7A). A detectable killing is
defined here as a mean specific lysis of more than 5% at least for
the two highest effector target ratios. Differentiated cells were
moderately killed only by cells from one grafted (no. 113) and one
control (co 1) DA rat (Fig. 7B). Splenocytes obtained from all
grafted and control LEW.1N rats killed ES cells (Fig. 7C).
However, a low cytotoxic activity against differentiated cells was
observed with splenocytes from only one grafted (no 120) and one
control (co 2) LEW.1N rat (Fig. 7D). The cytotoxic activity of
splenocytes from Wistar rats against ES cells appeared to be
reduced compared to the other strains (Fig. 7E). Splenocytes from
all animals failed to kill differentiated cells (Fig. 7F). However, a
short term culture with IL-2 was usually sufficient to increase their
cytotoxic activity against ES cells (Fig. 7G). Thus, a natural
cytotoxic activity against mouse ES cells exists not only in LOU/c
rats but also in other rat strains such as DA and LEW.1N.
NK cells appear to contribute to the rejection of ES cells
in vivo but further immune mechanisms might be
involved
The presence of NK cells with cytotoxic activity against ES cells
in naı ¨ve and transplanted rats suggest that they might influence the
outcome of the transplantation. However, in syngeneic 129Sv
Figure 5. Tumor growth in CsA-treated 129Sv mice and LOU/c
rats after injection of ES cells or in vitro differentiated cells. (A)
1610
6 ES cells or in vitro differentiated cells were injected subcutane-
ously at day 0 into syngeneic 129Sv mice (for the numbers of animals
see Table 2) which were treated daily with CsA (10 mg/kg body weight).
The tumor size was recorded every second day until day 100 using
linear calipers. The growth of tumors in individual mice is shown. Tumor
growth in female hosts is indicated by red lines and male hosts by blue
lines. (B) 1610
6 cells differentiated in vitro for 14 days were injected
subcutaneously into LOU/c rats (n=18) which were treated daily with
CsA (10 mg/kg body weight). The tumor size was recorded every
second day until day 100 using linear calipers. The growth of tumors in
individual rats is shown. Tumor growth in female hosts is indicated by
red and in male hosts by blue lines. One tumor in a female rat was not
progressive and remained very small until the end of the experiment. In
two male rats a tumor regression occurred.
doi:10.1371/journal.pone.0002622.g005
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PLoS ONE | www.plosone.org 7 July 2008 | Volume 3 | Issue 7 | e2622Figure 6. Lysis of ES and in vitro differentiated cells by NK cells derived from naı ¨ve LOU/c rats and expression analysis of MHC class I
molecules and NKG2D ligands. (A) Mean of specific lysis and standard deviation (SD) of triplicates of ES or in vitro differentiated cells at three
effector:target (E:T) ratios. Effector cells were lymphocytes obtained from spleens of 10 individual LOU/c rats by density gradient centrifugationo n
Biocoll. Results obtained with lymphocytes from female rats are indicated by open symbols and from male rats by filled symbols. (B) The mean
specific lysis and SD of triplicates of ES, YAC-1, and RMA target cells at three effector:target (E:T) ratios by freshly isolated NK cells or NK cell-depleted
splenocytes from naı ¨ve LOU/c rats are shown. The NK cell enriched fraction contained 86% and the NK cell depleted fraction 3% NKR-P1A-positive
cells as determined by flow cytometry. The results are representative for 3 independent experiments. (C) The mean specific lysis and SD of triplicates
of ES and YAC-1 cells at three effector:target (E:T) ratios by freshly isolated (open symbols) or 3 days in vitro with 1000 U/ml IL-2 stimulated (closed
symbols) mouse and rat NK cells are shown. The NK cell-enriched fractions contained more than 80% NK cells as determined by flow cytometry. The
results shown are representative for 3 independent experiments. (D) The expression of MHC class I molecules on ES and differentiated cells was
analyzed by flow cytometry using anti-H2K
b and anti-H2D
b Abs (full lines). The stainings with the isotype control are shown by the dotted lines. RMA
cells (H2
b) served as positive control for these antibodies. NKG2D ligands were stained with a recombinant mouse NKG2D-Fc chimeric protein and a
FITC-conjugated goat anti-human IgG antibody as secondary reagent (full lines). Stainings with the secondary reagent only are shown by the dotted
lines. YAC-1 cells (H2
a) served as positive controls for these stainings. The results shown are representative for more than 3 independent experiments.
(E) ES and as positive control YAC-1 cells were stained with the NKG2D-Fc chimeric protein and with mAbs specific for the NKG2D ligands H60, MULT-
1, and RAE-1. The mean+SD of the proportion of positive cells and the mean fluorescence intensity+SD determined in 6 independent experiments is
shown. (F) The mean inhibition+SD of specific lysis of ES and YAC-1 cells by soluble mouse NKG2D is shown as determined in 3 experiments. The
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functional NK cells which can kill the ES cells in vitro after IL-2
stimulation. To determine whether allogeneic mouse NK cells can
prevent teratoma growth in vivo, we injected the ES cells into SCID
mice (C.B-17, H2
d) which have no B and T cells but NK cells. In
100% (15/15) of the animals teratomas were observed within 100
days after injection of ES cells (Fig. 8A). Thus, the injection of ES
cells alone might not be sufficient to activate the NK cells in mice.
Therefore, we tried to inhibit the preexisting NK cell activity in rats.
Unfortunately, in rats a genetic model of NK cell deficiency is not
available. It has been shown that injection of high doses of
monoclonal antibodies against the NKR-P1A molecule can
transiently inhibit NK cell cytotoxicity in vivo [14]. We speculated
that a transient inhibition of NK cells could be sufficient to allow for
a differentiation of injected ES cells in vivo into a pluripotent and NK
cell resistant cell population which could then give rise to teratomas.
The treatment scheme and the efficiency of NK cell depletion are
showninFig.8Band 8C.In2 of8 maleLOUratssmalltumorswere
found at the injection site but none of the 6 control rats treated with
anisotypecontrolshowedatumor(Fig.8D).Takingintoaccountthe
limited efficiency of a transient NK cell inhibition, these data suggest
that NK cells could contribute to the control of teratoma growth but
likely further immune mechanisms are involved in the rejection of
mouse ES cells in CsA-treated rats.
Discussion
It is well known that mouse [8,10,15–18] and human ES cells
[19,20] can give rise to teratomas when injected into immunode-
ficient hosts. The ability of cells to form teratomas in such recipients
can even be used as an in vivo test for their pluripotency [21]. Mouse
ES cells can also form teratomas in syngeneic [9,22,23] and
allogeneic hosts [8,9,17] and even in xenogeneic recipients such as
rats [1,5]. The frequency of tumors varied in these studies. This is
probably depending on the ES cell lines used [24], the degree of
histoincompatibility between transplanted cells and recipients, the
immunosuppressive treatment of the recipients, and the site of
transplantation [24,25], especially when it is an immune-privileged
organ. The situation is even more complex after transplantation of in
vitrodifferentiated cells.Againteratomashavebeen observedinsome
studiesinsyngeneic[9,22],allogeneic[6]and xenogeneichosts[4,5].
However, the results might have been also strongly influenced by the
differentiation protocols and selection strategies [9–12].
We have used one ES cell line (MPI-II) and one differentiation
protocol [3,26] that after 14 days of culture results in about 95%
Tuj1-positive neuronal cells and about 30% TH-positive dopami-
nergic cells [3,26]. The same differentiation protocol has also been
successfully used for the dopaminergic differentiation of human
[27–29] and non-human primate ES cells [30,31]. These
differentiated mouse cells have been shown previously to improve
the amphetamine-induced rotational behavior in unilaterally 6-
OHDA-lesioned and not immunosuppressed rats after intrastriatal
transplantation [3]. However, these cells gave rise to teratomas in
2 of 15 CsA-treated animals [4].
Subcutaneous injection of either 1610
6 ES cells or differenti-
ated cells led to teratoma growth in about 95% of the syngeneic
129Sv recipients. It was surprising that neither frequency nor
growth of the tumors derived from differentiated cells were
significantly reduced. We have shown in a pilot experiment that a
10-fold reduction of the number of ES cells reduced the tumor
frequency. The proportion of undifferentiated cells which still
might have been present after in vitro differentiation was less than
10% [3]. Thus, it appears to be questionable whether only
completely undifferentiated ES cells can contribute to the
teratoma formation. In allogeneic mice and xenogeneic rats no
tumor growth was observed. A mismatch in minor histocompat-
ibility antigens was sufficient to suppress the tumorigenesis as
shown in C57BL/6 recipients which share the MHC haplotype
H2
b with 129Sv mice. Since both ES and differentiated cells
formed teratomas in allogeneic immunodeficient SCID/beige
mice the immune response was indeed responsible for the
suppression of tumors after allogeneic transplantation.
Immunosuppression with CsA did not augment the tumorigenic-
ity of the cells in allogeneic mice. However, this was different for
xenogeneicrat recipients.EScellswere notable toformteratomas in
CsA-treated rats but in vitro differentiated cells lead to progressive
tumor growth in about 50% of the animals. This finding clearly
indicates that differentiated cells must contain a tumorigeneic cell
population that is different from the ES cells. These cells might be
even more tumorigeneic than ES cells because this subpopulation of
cells present in differentiation cultures gave rise to teratomas in a
similar frequency as a homogenous ES cell population. The CsA-
treatment which suppresses the activation of T lymphocytes does
apparently not impair the rejection of ES cells. The rejection of the
novel tumorigenic cell population among differentiated cells in non
CsA-treated hosts must be mediated by a part of the immune system
which is affected by CsA such as cytotoxic T lymphocytes (CTL).
These observations challenge thecommonview that onlycompletely
undifferentiated ES cells can giverise to teratomas. Somecells which
arise in the differentiation culture obviously retain pluripotency. The
molecular characteristics of these cells are unknown. They might
represent a physiological differentiation step or, alternatively, a
pathologicalmiss-differentiationmightoccurinsomecellsduring the
in vitro differentiation culture. We assume that a pluripotent cell
population exists in the differentiation culture which is an
intermediate between ES cells and neuronal cells. These cells must
be different from neural rosette cells (R-NSC) because the
histopathological evaluation of the tumors from CsA-treated rats
indicated undoubtedly the growth of teratomas after injection of in
vitro differentiated cells and not a ‘‘rosette overgrowth’’ that has been
described recently after grafting of ES cell-derived R-NSCs [32].
Interestingly, the teratoma growth appeared to be accelerated in
male immunocompetent syngeneic mice and xenogeneic rats.
Therefore, the teratoma growth might be supported by male
hormones. The risk of teratoma formation appears to be influenced
by a complex interaction between sex and immune status of the
recipients that needs further exploration. Therefore, it will be of
interest to determine in further experiments the tumorigenicity of
female ES cells in female as well as in male recipients.
Rather little is known about the immune response that occurs
after transplantation of ES cells or cells differentiated from ES cells
[33–35]. We speculated that NK cells might be involved in the
mean of specific lysis of the target cells by rat NK cells at an effector to target ratio of 20:1 was determined as described above and adjusted to 100%.
For inhibition of lysis a soluble mouse NKG2D protein was added to the test at a concentration of 3 mg/ml. The relative lysis of the target cells
exposed to NKG2D was calculated. (G) The mean inhibition+SD of specific lysis of ES cells by soluble mouse NKG2D and various inhibitory antibodies
against NKG2D ligands is shown. The mean of specific lysis of the target cells by IL-2 activated mouse NK cells at an effector to target ratio of 10:1 was
determined as described above and adjusted to 100%. For inhibition of lysis a soluble mouse NKG2D protein or the indicated mAbs were added to
the test at a concentration of 3 mg/ml. The relative lysis of the target cells exposed to NKG2D or the mAbs was calculated.
doi:10.1371/journal.pone.0002622.g006
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PLoS ONE | www.plosone.org 9 July 2008 | Volume 3 | Issue 7 | e2622Figure 7. Lysis of ES and in vitro differentiated cells by splenocytes derived from rats 6 weeks after intracerebral grafting of in vitro
differentiated cells. Mean of specific lysis and SD of triplicates of ES cells (A, C, E, G) or in vitro differentiated cells (B, D, F) at three effector:target
(E:T) ratios. Effector cells were lymphocytes obtained by density gradient centrifugation on Biocoll from spleens of grafted (no. 113–117) or naı ¨ve (co1
and co2) DA rats (A, B), grafted (no. 118–122) or naı ¨ve (co1 and co2) LEW.1N rats (C, D), and grafted Wistar rats (no. 38, 39, 48, 49, 51, 52, 53, 54, 56,
57). The individual rats are indicated by symbols. (G) Mean of specific lysis and SD of triplicates of ES cells by lymphokine-activated killer (LAK) cells
derived from splenocytes of Wistar rats (no. 38, 48, 49, 51, 52, 54, 56) after culture for 4 days in the presence of 100 U/ml IL-2.
doi:10.1371/journal.pone.0002622.g007
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activity is not generally impaired by CsA, although in humans some
effects of CsA on NK subpopulations have been described recently
[36]. Furthermore, mouse as well as human ES cells might be a target
for NK cells because they express no or low amounts of MHC class I
molecules [8,17,37,38] which serve as ligands for inhibitory NK
receptors [39]. The expression of MHC class I molecules has been
described to increase during in vitro differentiation of ES cells [40,41].
CellswhichexpressnoMHCclassImoleculesmightfailtoinhibitthe
cytotoxic NK cell activity [42]. Human NK cells have been shown to
kill human ES cell lines which expressed small amounts of ligands for
the activating NK receptor NKp44 [37]. On the other hand it has
been reported that mouseNK cells are not important for the rejection
of human ES cells in vivo [19]. Alternatively, the complement system
has been shown to contribute to the control of teratoma growth after
transplantation of ES cells [18].
We found a high cytotoxic activity of splenocytes derived from
naı ¨ve rats against the ES cells and a low activity against
differentiated cells. Flow cytometry did not indicate the presence
of MHC class I molecules (H2K and H2D) on these cells and the
differentiation only moderately increased H2K expression.
Interestingly, the ES cells expressed ligands for the activating
NK receptor NKG2D. Recognition of these ligands by NKG2D
on NK cells is known to trigger cytotoxicity [43] and the killing of
the ES cells by rat NK cells as well as IL-2 activated mouse NK
cells was indeed dependent on NKG2D. NKG2D ligands were
down-regulated during differentiation culture and this finding
explains the reduced susceptibility of these targets to natural
cytotoxic cells much better than the observed moderate up-
regulation of H2K molecules. These results could suggest that ES
cells were rapidly destroyed in immunocompetent as well as in
CsA-treated rat recipients by NK cells before teratomas were
formed. Differentiated cells which are NK cell resistant but still
tumorigenic could have given rise to teratomas in CsA-treated rats
which fail to reject these cells due to the impaired adaptive
immune system. Although an antibody-mediated NK cell
depletion is not as effective as a genetic NK cell deficiency, our
respective experiment resulted in small teratomas in a subgroup of
rats, suggesting that NK cells might be involved in the rejection of
ES cells in CsA-treated rats. However, in addition NK cells, likely
further immune mechanisms contribute to the removal of ES cells.
The unimpaired teratoma growth in SCID mice could even argue
that mouse NK cells are not important at all for the rejection of ES
cells [19]. However, one should notice that mouse NK cells had to
be activated by IL-2 to become able to kill the ES cells in vitro.
Therefore, the effect of mouse and rat NK cells on teratoma
growth might depend on the degree of an inflammatory response
after transplantation which can lead to NK cell activation.
Figure 8. Analysis of effects of NK cells on the rejection of ES cells in vivo. (A) 1610
6 ES cells were injected subcutaneously at day 0 into 15
T and B cell deficient SCID mice which have functional NK cells. The tumor size was recorded every second day until day 100 using linear calipers. The
growth of tumors in individual mice is shown. Tumor growth in female hosts is indicated by red lines and in male hosts by blue lines. In one animal a
tumor regression was observed. (B) The treatment scheme of rats receiving an NK cells depleting antibody (anti-NKR-P1A) or an isotype control is
shown. (C) The mean proportion plus SD of NK cells in the blood of male LOU rats receiving the anti-NKR-P1A mAb (n=8) or the isotype control
(n=6) is shown. Blood cells were stained with the respective mAb and analyzed by flow cytometry after lysis of erythrocytes. (D) The proportion of
the male rats in which tumors were found at autopsy is indicated. The size of the tumors was 12 mm
3 and 16 mm
3, respectively. Both were palpable
for more than 30 days before autopsy.
doi:10.1371/journal.pone.0002622.g008
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Due to their expression at the cell surface they are potentially
useful for sorting of ES and differentiated cells. NKG2D ligands
include in the mouse RAE-1, H60, and MULT-1 [43]. These
ligands are not expressed normally but they can become induced
in response to stress, such as heat shock [44], virus infection [45],
or genotoxic stress [46]. They might signal the presence of
potentially dangerous cells to the immune system [47]. The
expression of these ligands in tumor cells is known to contribute to
the tumor surveillance by the immune system [43]. The NKG2D
ligands found to be expressed on the ES cells belong mainly to the
RAE-1 family. This finding is in accordance with one previous
study, however, these authors reported that RAE-1 molecules on
mouse ES cells do not confer susceptibility to lysis by NK cells
[48]. It remains to be elucidated whether the expression of these
ligands on ES cells has a physiological function. NKG2D ligands
could allow, e. g., for the removal of displaced and potentially
dangerous pluripotent cells by the immune system.
Recently it has been reported that mouse ES cells are resistant
to antigen-specific CTL due to the expression of serpin-6 which is
an endogenous inhibitor of granzyme B [40]. However, the MPI-
II cells analyzed here were susceptible to granule exocytosis-
mediated killing by rat NK cells and also by peptide-specific mouse
CTL (own unpublished data). Thus, ES cells are not generally
protected against cellular cytotoxicity. Human ES cell lines were
also reported to be susceptible to human CTL [49]. It has to be
investigated further whether ES cell lines vary in their suscepti-
bility against the cytotoxic mechanisms of the immune system.
Much research efforts are currently directed towards the
establishment of pluripotent cells from individuals which might be
subsequently used for syngeneic transplantations before or after in
vitro differentiation. These strategies might be associated with an
increased risk of teratoma formation. Thus, it might be worthwhile
to thoroughly evaluate whether allogeneic stem cells can be used as
an effective and safe new therapeutic tool in regenerative medicine.
Materials and Methods
ES cell culture and neuronal differentiation culture
Undifferentiated mouse ES cells (MPI-II, 129Sv strain, XY
karyotype) were expanded on gelatin-coated cell culture dishes in
Glasgow minimal essential medium (GIBCO-Invitrogen, Karls-
ruhe, Germany) containing 1% fetal calf serum (FCS), 10%
knockout replacement, 2 mM glutamine, 0.1 non essential amino
acids, 1 mM sodium pyruvate, 0.1 mM 2-mercaptoethanol,
2000 U/ml leukemia inhibitory factor (GIBCO). The neuronal
differentiation was induced in a culture on mitomycin C-
inactivated PA6 feeder cells as described [3,26]. On day 14 of
the culture cells were used for experiments and are named
throughout this study as ‘‘differentiated cells’’.
Culture of cell lines
The mouse lymphoma cell lines YAC-1 (H2
a) and RMA (H2
b)
were maintained in NaHCO3-buffered Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% FCS (Biochrom, Berlin,
Germany), 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml
penicillin, and 100 mg/ml streptomycin. PA6 feeder cells were
cultured in the same medium on gelatin-coated cell culture plates.
Animal experiments
Animals were bred in the central animal facility of the Medical
Faculty of the University of Go ¨ttingen. Animal experiments had
been approved bythe local government.Rats(DA,LEW.1N,LOU/
c, Wistar) and immunocompetent mice (129Sv, C3H/HeN,
C57BL/6) were conventionally housed whereas severe combined
immunodeficient SCID/beige (C.B-17/IcrHsd-scid-bg) and SCID
(C.B-17/Ztm-scid) mice were kept under pathogen-free conditions.
A subgroup of animals received daily intraperitoneal injections of
CsA (10 mg/kg, Sandimmune, Novatis Pharma, Nu ¨rnberg) starting
two days before grafting. For the depletion of NK cells, some rats
received in addition to CsA intraperitoneal injections of the
monoclonal antibody (mAb) anti-NKR-P1A (clone 10/78, mouse
IgG1, BD Biosciences, Heidelberg, Germany) or the respective
isotype control (clone PPV-06, mouse IgG1, Exbio, Prague, Czech
Republic). The anti-NKR-P1A mAb (clone 10/78) is directed
against the same epitope as the mAb (clone 3.2.3) which has been
used previously to deplete NK cells in rats [14]. One mg of the
respective antibodies were given one day before the injection of ES
cells followed by 0.5 mg at day 4 after cell transplantation. Blood
samples were taken before starting these experiments, at day 0 and 4
days after cell transplantation, and at autopsy (day 92) in order to
determine the proportion of NKcellsinthebloodbyflow cytometry.
For the analysis of subcutaneous tumor growth ES or differentiated
cells were injected in 100 ml phosphate-buffered saline (PBS) into the
flankofthe animals.Tumor growthwasmonitored everysecondday
by palpation and size was recorded using linear calipers. The tumor
volume was calculated by the formula V=pabc/2, where a, b, c are
the orthogonal diameters. Animals were sacrificed before day 100
when a tumor volume of 1 cm
3 in mice and 5 cm
3 in rats was
reached, when a weight loss of more than 10% occurred, or when
any behavioral signs of pain or suffering were observable. Autopsies
of all animals were performed. Tumor tissue was immediately frozen
in liquid nitrogen or placed in phosphate-buffered 4% formalin for
16 h and then embedded in paraffin. Spleens and lymph nodes were
removed for subsequent immunological analyses. The transplanta-
tion of cells into the striatum of unilaterally 6-OHDA-lesioned rats
was performed as previously described [3]. These animals were
sacrificed 6 weeks after transplantation.
Histology, immunohistochemistry, and
immunofluorescence
Tissue sections (2.5 mm) were stained with hematoxylin and eosin
(HE) for histological examinations. For immunohistochemistry,
intrinsic peroxidase activity was blocked by incubation with 5%
H2O2 in PBS for 20 minutes after deparaffinization. Non-specific
antibody binding was inhibited with 10% FCS in PBS for
25 minutes. Microwave pre-treatment for antigen retrieval was
regularly performed with exception of the sections for the NeuN and
glialfibrillaryacidicprotein(GFAP)stainings.Immunohistochemical
staining was performed with an avidin-biotin technique. The
primary mAbs for immunohistochemistry were anti-NeuN (1:100,
clone MAB277, mouse IgG1, Chemicon, Temecula, CA, USA),
anti-GFAP (1:50, clone 6F2, mouse IgG1, Dako, Hamburg,
Germany), anti-mouse CD3 (1:200, clone CD3-12, rat IgG1,
Serotec, Du ¨sseldorf, Germany), anti-rat CD3 (1:500, clone 1F4,
mouse IgM, Serotec), anti-mouse CD45R/B220 (1:200, clone RA3-
6B2, rat IgG2a, BD Biosciences,), anti-rat CD45R (1:200, clone
HIS24, mouse IgG2b, BD Biosciences), anti-mouse Mac3 (1:200,
cloneM3/84,ratIgG1,BDBiosciences),anti-ratCD68(1:500,clone
ED1, mouse IgG1, Serotec), anti-Ki67 (1:20, clone Tec3, rat IgG2a,
Dako), and anti-OCT3/4 (1:50, clone 40, mouse IgG1,B D
Biosciences). Rat natural killer cells were stained on frozen sections
(5 mm)usingananti-NKR-P1AmAb (clone 10/78,mouse IgG1,B D
Biosciences). Immunofluorescence stainings of colonies of in vitro
differentiated cells were performed and quantified as described
before [3] using mAbs against OCT3/4, Ki67, and Tuj1 (1:200,
clone TUJ1 1-15-79, rabbit IgG, CRP Inc., Berkeley, CA, USA). To
roughly estimate the frequency of OCT3/4-positive colonies after
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stained colonies were counted.
Flow cytometry
Flow cytometry was performed on a FACScan
TM flow
cytometer (BD Biosciences) using CellQuest
TM software. The cell
surface expression of MHC class I molecules was analyzed using
locus and haplotype-specific mAbs anti-H2K
b (clone CTKb,
mouse IgG2a, phycoerythrin (PE)-conjugated, Caltag Laboratories,
Hamburg, Germany), and anti-H2D
b (clone CTDb, mouse IgG2a,
PE-conjugated, Caltag). A recombinant mouse NKG2D-Fc
chimeric protein (139-NK; R&D Systems) was used to detect cell
surface expression of NKG2D ligands. A polyclonal fluorescein
isothiocyanate (FITC)-conjugated goat anti-human IgG (109-095-
098; Jackson Laboratories, Dianova, Hamburg, Germany) served
as secondary reagent. The following mAbs were used to detect
specific NKG2D ligands: anti-RAE-1 (pan-specific, clone 186107,
rat IgG2a, R&D Systems), anti-H60 (clone 205326, rat IgG2a,
R&D Systems), and anti-MULT-1 (clone 237104, rat IgG2a,
R&D Systems). A polyclonal FITC-conjugated goat anti-rat IgG
(212-095-082; Jackson Laboratories, Dianova) served as secondary
reagent. The purity of rat NK cells separated by magnetic cell
sorting (MACS) and the proportion of NK cells in the blood of rats
were assessed using an anti-NKR-P1A mAb (clone 10/78, mouse
IgG1, PE-conjugated, Caltag). Erythrocytes in blood samples were
lysed before analysis using a FACS lysing solution (BD Biosciences)
according to the manufactures instructions. The purity of MACS-
separated mouse NK cells was assessed using the pan-NK cell
marker CD49b (clone DX5, rat IgM, PE-conjugated, Caltag).
Isotype controls were purchased from Caltag.
Effector cells and
51Chromium release assays
Lymphocytes were obtained from spleens or lymph nodes using
a Tenbroeck homogenizer. Erythrocytes were removed from
splenocytes by density gradient centrifugation on Biocoll (Bio-
chrom). The cells were used either directly as cytotoxic effector
cells or cultured for 4 days in DMEM supplemented with 10%
FCS, 50 mM 2-mercaptoethanol, and 1000 U/ml IL-2 (Chiron,
Amsterdam, Netherlands) to obtain lymphokine-activated killer
(LAK) cells. Rat NK cells were isolated by MACS using a biotin-
conjugated anti-NKR-P1A Ab (clone 10/78, mouse IgG1,B D
Biosciences) and paramagnetic anti-biotin micro beads (130-090-
485, Miltenyi Biotec, Bergisch-Gladbach, Germany) according to
the manufactures instructions. Mouse NK cells were isolated using
a negative selection kit (NK cell isolation Kit mouse, 130-090-864;
Miltenyi Biotec). The kit contains a cocktail of antibodies against
CD4, CD5, CD8a, CD19, Ly-6G, and Ter-119 and depletes the
non-NK cells. To activate NK cells in vitro they were cultured in
DMEM supplemented with 10% FCS, 50 mM 2-mercaptoethanol,
and 1000 U/ml IL-2.
51Chromium release assays were performed
as previously described [50,51]. A recombinant mouse NKG2D-
Fc chimeric protein (139-NK) purchased from R&D Systems
(Wiesbaden, Germany) was used to inhibit the part of lysis of target
cells which was dependent on the expression of NKG2D ligands.
Similarly, antibodies which block the binding of NKG2D to RAE-
1b (MAB17581, clone 199205, rat IgG2a, R&D Systems), RAE-1a
and RAE-1c (MAB 1758, clone 199215, ratIgG2a, R&D Systems),
and H60 (clone 205326, rat IgG2a, R&D Systems) were used for
blocking experiments. A rat IgG2a isotype control was purchased
from Caltag.
Statistics
A nonparametric ANOVA-like method for longitudinal data
based on ranks was used [52] to compare the tumor growth in
different experimental groups. Due to numerical issues we
compared tumor growth curves longitudinally using the following
time points: 10, 20, 30, 40, and 50 days post injection.
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